psychedelics; depression; anxiety; ptsd; addiction

The psychedelic drug development landscape has reached an inflection point in early 2026, with Compass Pathways achieving the first positive Phase 3 psilocybin trial results in June 2025, while Lykos Therapeutics' MDMA rejection has reshaped industry expectations for regulatory rigor. Six...

Ibogaine: Promise and Practicalities for Transforming Addiction Treatment Ibogaine is rapidly garnering attention as a potentially revolutionary treatment for addiction and related mental health disorders—a beacon of hope in landscapes often characterized by despair and systemic inadequacy...

* Psychedelics are not panaceas, but they offer mechanisms of action distinct from conventional treatments. Substances such as MDMA, psilocybin, ibogaine, ketamine, and 5-MeO-DMT are demonstrating the capacity to disrupt entrenched neurobiological patterns associated with trauma, addiction, and...

Psychedelics have helped me and many others that I know through real dark times of addiction and depression. My own breakthrough with psychedelics provided the breaking down of my belief systems and reawakened an overwhelmingly empowering sense of my own ability to change. I’m super excited...